Moderna announced Thursday the company is developing a vaccine that will protect against COVID-19 and the flu with only a single dose.
“Today we are announcing the first step in our novel respiratory vaccine program with the development of a single dose vaccine that combines a booster against COVID-19 and a booster against flu,” CEO Stéphane Bancel said in a statement. “We believe Moderna could be first to market in this important new opportunity.”
The drugmaker also revealed its work on an mRNA pediatric vaccine to combine its treatments for respiratory syncytial virus and human metapneumovirus vaccine. The company is still carrying out clinical trials for an RSV vaccine for adults.
Amid the announcement, Moderna’s stock rose nearly 8% Thursday.
The mRNA Moderna COVID-19 vaccine has applied for full authorization approval from the FDA. The agency granted Pfizer full permission in August, just days before Moderna completed its application.
On Wednesday, Novvax said it had begun studies to test its version of a drug that combines flu and COVID protections.